Diabetes: RAS inhibition: Probably not a one-size-fits-all approach

Drazenka Pongrac Barlovic, Mark E. Cooper

Research output: Contribution to journalShort SurveyResearchpeer-review

Abstract

Blockade of the reninangiotensin system does not seem to prevent early nephropathy in individuals with type 1 diabetes who are normoalbuminuric and normotensive, but both the angiotensin-converting-enzyme inhibitor enalapril and the angiotensin-receptor blocker losartan seem to retard retinopathy.

Original languageEnglish
Pages (from-to)669-670
Number of pages2
JournalNature Reviews Nephrology
Volume5
Issue number12
DOIs
Publication statusPublished - Dec 2009
Externally publishedYes

Cite this

@article{91a46e5afc9742ab8f22ee2579f51280,
title = "Diabetes: RAS inhibition: Probably not a one-size-fits-all approach",
abstract = "Blockade of the reninangiotensin system does not seem to prevent early nephropathy in individuals with type 1 diabetes who are normoalbuminuric and normotensive, but both the angiotensin-converting-enzyme inhibitor enalapril and the angiotensin-receptor blocker losartan seem to retard retinopathy.",
author = "Barlovic, {Drazenka Pongrac} and Cooper, {Mark E.}",
year = "2009",
month = "12",
doi = "10.1038/nrneph.2009.189",
language = "English",
volume = "5",
pages = "669--670",
journal = "Nature Reviews Nephrology",
issn = "1759-5061",
publisher = "Nature Publishing Group",
number = "12",

}

Diabetes : RAS inhibition: Probably not a one-size-fits-all approach. / Barlovic, Drazenka Pongrac; Cooper, Mark E.

In: Nature Reviews Nephrology, Vol. 5, No. 12, 12.2009, p. 669-670.

Research output: Contribution to journalShort SurveyResearchpeer-review

TY - JOUR

T1 - Diabetes

T2 - RAS inhibition: Probably not a one-size-fits-all approach

AU - Barlovic, Drazenka Pongrac

AU - Cooper, Mark E.

PY - 2009/12

Y1 - 2009/12

N2 - Blockade of the reninangiotensin system does not seem to prevent early nephropathy in individuals with type 1 diabetes who are normoalbuminuric and normotensive, but both the angiotensin-converting-enzyme inhibitor enalapril and the angiotensin-receptor blocker losartan seem to retard retinopathy.

AB - Blockade of the reninangiotensin system does not seem to prevent early nephropathy in individuals with type 1 diabetes who are normoalbuminuric and normotensive, but both the angiotensin-converting-enzyme inhibitor enalapril and the angiotensin-receptor blocker losartan seem to retard retinopathy.

UR - http://www.scopus.com/inward/record.url?scp=73849136377&partnerID=8YFLogxK

U2 - 10.1038/nrneph.2009.189

DO - 10.1038/nrneph.2009.189

M3 - Short Survey

VL - 5

SP - 669

EP - 670

JO - Nature Reviews Nephrology

JF - Nature Reviews Nephrology

SN - 1759-5061

IS - 12

ER -